Prognostic serum miRNA biomarkers associated with Alzheimer’s disease shows concordance with neuropsychological and neuroimaging assessment - Cheng, L; Doecke, J D; Sharples, R A; Villemagne, V L; Fowler, C J; Rembach, A; Martins, R N; Rowe, C C; Macaulay, S L; Masters, C L; Hill, A F (Molecular psychiatry, 2015)
Keywords: 38; 38/39; 38/91; 45; 45/77; 631/208; 631/378; 692/53/2423; 692/699/476; Aged; Aged, 80 and over; Alzheimer Disease - blood; Alzheimer Disease - diagnosis; Alzheimer Disease - genetics; Alzheimer's disease; Amyloid; Apolipoprotein E; Apolipoproteins; Behavioral Sciences; Biochemistry; Biological Psychology; Biomarkers; Biomarkers - blood; Case-Control Studies; Cognitive ability; Development and progression; Diagnosis; Disease; Exosomes; Exosomes - genetics; Female; Genetic aspects; Genetic markers; Genetic Testing; Health aspects; Humans; Lifestyles; Male; Medical imaging; Medicine; Medicine & Public Health; Methods; MicroRNA; MicroRNAs; MicroRNAs - blood; miRNA; Molecular biology; Neurodegenerative diseases; Neuroimaging; Neuroimaging - methods; Neuropsychological Tests; Neuropsychology; Neurosciences; Non-coding RNA; original-article; Pharmacotherapy; Positron emission tomography; Prognosis; Psychiatric research; Psychiatry; Reproducibility of Results; Reverse transcription; Risk factors; Sensitivity and Specificity; Sequence Analysis, RNA; Tomography; Transcriptome; Australia